2356 GMT - The almost certain withdrawal of the CSL-marketed Tavneos therapy in Europe only adds to Macquarie's caution toward the Australian biotechnology company. An analyst at the investment bank tells clients in a note that a European Commission ruling on the treatment appears to be a formality, and trims EPS forecasts by 3% for fiscal 2027 and by 4% for fiscal 2028. The analyst reiterates a neutral rating on the stock and reminds readers of the significant near-term earnings uncertainty across CSL's core business segments, plus ongoing medium-term competitive risks. Target price rises 2.7% to 114.00 Australian dollars, reflecting currency moves. Shares are at A$115.39 ahead of the open. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

June 29, 2026 19:56 ET (23:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.